7765 RAPID
- 0.785
- +0.015+1.95%
RAPID News
Positive Phase 2 Results and Rapid Efficacy Drive Buy Rating for Atossa Therapeutics
Aquestive Therapeutics' Anaphylm: Rapid and Reliable Allergy Treatment Gains 'Buy' Rating
ASP Isotopes, Inc.: Rapid Production Milestone and Strategic Positioning Justify Buy Rating
Buy Rating Affirmed for ESTA on Rapid U.S. Adoption of Motiva Implants
Buy Rating Affirmed: Nuvalent's Rapid Clinical Progress and Best-in-Class Drug Profile Signal Strong Future Success
Buy Rating Affirmed for Personalis Amidst Rapid Commercialization and Strong Tempus AI Partnership
Buy Rating Justified by Ocular Therapeutix's Rapid SOL-1 Trial Progress and Positive FDA Feedback on SOL-R
Morgan Stanley Remains a Hold on Rapid Micro Biosystems (RPID)
Iris Energy: Strong Buy Rating on Rapid Expansion and Growth Potential
Analysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)
Iris Energy: Strong Buy Rating on Rapid Exahash Expansion and Strategic AI Hosting Foray
Chardan Adjusts Price Target on VinFast Auto to $13 From $11 on Global Ramp-up, Rapid Revenue Growth Expectations, Reiterates Buy Rating
Analysts Offer Insights on Technology Companies: Rapid7 (RPD) and Zoom Video Communications (ZM)
Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track
Analysts Have Conflicting Sentiments on These Technology Companies: Rapid7 (RPD), CDW (CDW) and Alpha and Omega (AOSL)
Analysts Conflicted on These Technology Names: Paycor HCM (PYCR), Rapid7 (RPD) and Paylocity (PCTY)
RBC Capital Reiterates Outperform on Rapid7, Maintains $70 Price Target
Rapid7 Analyst Ratings
Rapid7 (RPD) Receives a Hold From D.A. Davidson
Analysts Have Conflicting Sentiments on These Technology Companies: ARM Holdings PLC ADR (ARM), Qualys (QLYS) and Rapid7 (RPD)
No Data